Business Context and Reporting Period
Tactile Systems Technology, Inc. (TCMD) is a medical technology company developing devices for chronic diseases, primarily lymphedema and airway clearance. This Form 10-Q covers the quarterly period ended June 30, 2026. The company operates as a single segment and is an accelerated filer.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $85.7 million | $161.0 million |
| Gross Profit | $65.3 million | $123.0 million |
| Gross Margin | 76% | 76% |
| Net Income | $7.8 million | $6.0 million |
| Diluted EPS | $0.34 | $0.26 |
| Cash and Equivalents | $69.9 million (as of June 30, 2026) | N/A |
| Operating Cash Flow (6mo) | N/A | $2.9 million |
| Debt | $0 outstanding borrowings | $0 outstanding borrowings |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9% year-over-year (YoY) for the quarter and 15% YoY for the six-month period. Lymphedema product revenue drove the growth, up 12% (quarter) and 17% (six months), while airway clearance revenue declined 7% in the quarter but grew 6% over six months.
- Profitability: Net income surged 142% YoY for the quarter ($7.8M vs $3.2M) and increased significantly for the six-month period ($6.0M vs $0.2M). Operating income improved from a loss of $0.5M in the prior six-month period to $5.3M.
- Expense Management: Operating expenses increased 7% for the quarter and 12% for six months, primarily due to higher personnel compensation and R&D investments. Interest expense dropped 95% YoY for the quarter following the repayment of a term loan in July 2025.
- Acquisitions: The company acquired LymphaTech, Inc. in February 2026 for approximately $12.1 million in total consideration (including contingent consideration), adding a 3D measurement platform for lymphedema.
Guidance, Outlook, and Risks
- Strategic Initiatives: In April 2026, the company entered a 3-year exclusive distribution agreement with ElastiMed, Inc. for the MyoSleeve device, paying a $3.0 million upfront fee. Commercial availability is expected in the second half of 2026.
- Seasonality: Management notes that Q1 typically sees reduced demand due to insurance deductibles, with higher revenue expected in Q3 and Q4.
- Liquidity: The company maintains a $40.0 million revolving credit facility with no outstanding borrowings as of June 30, 2026. It is in compliance with all covenants.
- Share Repurchases: Under a $25.0 million program authorized in October 2025, the company repurchased 249,150 shares for $6.4 million during the first six months of 2026. Approximately $18.7 million remains available.
- Legal Contingency: Two qui tam complaints regarding False Claims Act violations were settled in principle in April 2026 for approximately $0.6 million plus legal fees. A final settlement agreement was executed in July 2026.
- Risks: Key risks include reimbursement challenges from third-party payers, supply chain disruptions, inflation, and the ability to integrate acquisitions.
Investor Verification Checklist
- Verify the commercial launch timeline and revenue contribution of the new MyoSleeve distribution agreement.
- Monitor the integration progress and revenue impact of the LymphaTech acquisition.
- Review the status of the settled qui tam litigation to ensure no further liabilities arise.
- Assess the sustainability of operating cash flows, which were significantly lower in the first six months of 2026 ($2.9M) compared to the prior year ($15.2M) due to working capital changes and acquisition costs.
- Track the utilization of the remaining $18.7 million share repurchase authorization.